| [1] |
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016[J]. CA Cancer J Clin, 2016, 66(1):7-30.
|
| [2] |
Nevala-Plagemann C, Hidalgo M, Garrido-Laguna I. From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer[J]. Nat Rev Clin Oncol, 2020, 17(2):108-123.
|
| [3] |
Strobel O, Neoptolemos J, Jäger D, et al. Optimizing the outcomes of pancreatic cancer surgery[J]. Nat Rev Clin Oncol, 2019, 16(1):11-26.
|
| [4] |
Hu Q, Wang D, Chen Y, et al. Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma[J]. Radiat Oncol, 2019, 14(1):120.
|
| [5] |
Park W, Chawla A, O'Reilly EM. Pancreatic cancer: a review[J]. JAMA, 2021, 326(9):851-862.
|
| [6] |
Klaiber U, Hackert T, Neoptolemos JP. Adjuvant treatment for pancreatic cancer[J]. Transl Gastroenterol Hepatol, 2019, 4:27.
|
| [7] |
Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer[J]. N Engl J Med, 2004, 350(12):1200-1210.
|
| [8] |
Neoptolemos JP, Stocken DD, Bassi C, et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial[J]. JAMA, 2010, 304(10):1073-1081.
|
| [9] |
Oettle H, Neuhaus P, Hochhaus A, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial[J]. JAMA, 2013, 310(14):1473-1481.
|
| [10] |
Neoptolemos JP, Palmer DH, Ghaneh P, et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4):a multicentre, open-label, randomised, phase 3 trial[J]. Lancet, 2017, 389(10073):1011-1024.
|
| [11] |
Conroy T, Hammel P, Hebbar M, et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer[J]. N Engl J Med, 2018, 379(25):2395-2406.
|
| [12] |
Frei E 3rd. Clinical cancer research: an embattled species[J]. Cancer, 1982, 50(10):1979-1992.
|
| [13] |
Seufferlein T, Uhl W, Kornmann M, et al. Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)-a randomized phaseⅡtrial of the AIO pancreatic cancer group[J]. Ann Oncol, 2023, 34(1):91-100.
|
| [14] |
Ghaneh P, Palmer D, Cicconi S, et al. Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial[J]. Lancet Gastroenterol Hepatol, 2023, 8(2):157-168.
|
| [15] |
Katz MH, Shi Q, Ahmad SA, et al. Preoperative modified FOLFIRINOX treatment followed by capecitabine-based chemoradiation for borderline resectable pancreatic cancer: alliance for clinical trials in oncology trial A021101[J]. JAMA Surg, 2016, 151(8):e161137.
|
| [16] |
国家卫生健康委员会办公厅. 胰腺癌诊疗指南(2022年版)[J]. 临床肝胆病杂志, 2022, 38(5):1006-1030.
|
| [17] |
Nakao A, Kanzaki A, Fujii T, et al. Correlation between radiographic classification and pathological grade of portal vein wall invasion in pancreatic head cancer[J]. Ann Surg, 2012, 255(1):103-108.
|
| [18] |
Groot VP, Rezaee N, Wu W, et al. Patterns, timing, and predictors of recurrence following pancreatectomy for pancreatic ductal adenocarcinoma[J]. Ann Surg, 2018, 267(5):936-945.
|
| [19] |
Versteijne E, Suker M, Groothuis K, et al. Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: results of the Dutch randomized phase Ⅲ PREOPANC trial[J]. J Clin Oncol, 2020, 38(16):1763-1773.
|
| [20] |
Motoi F, Satoi S, Honda G, et al. A single-arm, phase Ⅱ trial of neoadjuvant gemcitabine and S1 in patients with resectable and borderline resectable pancreatic adenocarcinoma: prep-01 study[J]. J Gastroenterol, 2019, 54(2):194-203.
|
| [21] |
Labori KJ, Lassen K, Hoem D, et al. Neoadjuvant chemotherapy versus surgery first for resectable pancreatic cancer [Norwegian Pancreatic Cancer Trial-1 (NorPACT-1)] - study protocol for a national multicentre randomized controlled trial[J]. BMC Surg, 2017, 17(1):94.
|
| [22] |
Motoi F, Kosuge T, Ueno H, et al. Randomized phase Ⅱ/Ⅲ trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP05)[J]. Jpn J Clin Oncol, 2019, 49(2):190-194.
|
| [23] |
Versteijne E, van Dam JL, Suker M, et al. Neoadjuvant chemoradiotherapy versus upfront surgery for resectable and borderline resectable pancreatic cancer: long-term results of the Dutch randomized PREOPANC trial[J]. J Clin Oncol, 2022, 40(11):1220-1230.
|
| [24] |
Rangelova E, Wefer A, Persson S, et al. Surgery improves survival after neoadjuvant therapy for borderline and locally advanced pancreatic cancer: a single institution experience[J]. Ann Surg, 2021, 273(3):579-586.
|
| [25] |
Amin MB, Greene FL, Edge SB, et al. The Eighth Edition AJCC Cancer Staging Manual: continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging[J]. CA Cancer J Clin, 2017, 67(2):93-99.
|
| [26] |
Hackert T, Sachsenmaier M, Hinz U, et al. Locally advanced pancreatic cancer: neoadjuvant therapy with folfirinox results in resectability in 60% of the patients[J]. Ann Surg, 2016, 264(3):457-463.
|
| [27] |
Philip PA, Lacy J, Portales F, et al. Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT):a multicentre, open-label phase 2 study[J]. Lancet Gastroenterol Hepatol, 2020, 5(3):285-294.
|
| [28] |
Ferrone CR, Marchegiani G, Hong TS, et al. Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer[J]. Ann Surg, 2015, 261(1):12-17.
|